Cargando…

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study

PURPOSE: The development of oestrogen resistance is a major challenge in managing hormone-sensitive metastatic breast cancer. Saracatinib (AZD0530), an oral Src kinase inhibitor, prevents oestrogen resistance in animal models and reduces osteoclast activity. We aimed to evaluate the efficacy of sara...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oswald, Ailsa J., Symeonides, Stefan N., Wheatley, Duncan, Chan, Stephen, Brunt, Adrian Murray, McAdam, Karen, Schmid, Peter, Waters, Simon, Poole, Christopher, Twelves, Chris, Perren, Timothy, Bartlett, John, Piper, Tammy, Chisholm, Eve Macdonald, Welsh, Michelle, Hill, Robert, Hopcroft, Lisa E. M., Barrett-Lee, Peter, Cameron, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147753/ https://www.ncbi.nlm.nih.gov/pubmed/36859649 http://dx.doi.org/10.1007/s10549-023-06873-8

Ejemplares similares

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
por: McGivern, Niamh, et al.
Publicado: (2017)

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
por: Kaye, S, et al.
Publicado: (2012)

Exploring the benefits of in-diet versus repeated oral dosing of saracatinib (AZD0530) in chronic studies: insights into pharmacokinetics and animal welfare
por: Vasanthi, Suraj S., et al.
Publicado: (2023)

Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy
por: Sharma, Shaunik, et al.
Publicado: (2021)

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)
por: Huang, R Y-J, et al.
Publicado: (2013)

A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease
por: Nygaard, Haakon B, et al.
Publicado: (2015)

Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
por: Baird, Kristin, et al.
Publicado: (2020)

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines
por: Gwanmesia, Patricia Mambou, et al.
Publicado: (2009)

AZD0530 sensitizes drug‐resistant ALK‐positive lung cancer cells by inhibiting SRC signaling
por: Zhao, Yi, et al.
Publicado: (2017)

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial
por: van Dyck, Christopher H., et al.
Publicado: (2019)

Synergistic effect of STAT3-targeted small interfering RNA and AZD0530 against glioblastoma in vitro and in vivo
por: Liu, Qingjun, et al.
Publicado: (2019)

SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma
por: Heusschen, Roy, et al.
Publicado: (2016)

Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
por: Williams, Eleanor, et al.
Publicado: (2021)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib
por: Lang, Liwei, et al.
Publicado: (2018)

Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo
por: Du, Guifang, et al.
Publicado: (2020)

Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro
por: Shin, Jin Soo, et al.
Publicado: (2018)

Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants
por: Thompson, Summer L., et al.
Publicado: (2021)

PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines
por: Nakachi, I, et al.
Publicado: (2016)

Gut dysbiosis following organophosphate, diisopropylfluorophosphate (DFP), intoxication and saracatinib oral administration
por: Gage, Meghan, et al.
Publicado: (2022)

An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain
por: Danson, Sarah, et al.
Publicado: (2019)

CERN: Minus omega
Publicado: (1997)

Stabilizing the minus ends?
por: Tuma, Rabiya S.
Publicado: (2005)

Minus 15 Prozent
por: Freisleben, Christian F.
Publicado: (2021)

Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma
por: Lang, Liwei, et al.
Publicado: (2019)

Post-status epilepticus treatment with the Fyn inhibitor, saracatinib, improves cognitive function in mice
por: Luo, Xin-Ming, et al.
Publicado: (2021)

Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma
por: Liao, Xia, et al.
Publicado: (2020)

A minus end checkpoint
por: LeBrasseur, Nicole
Publicado: (2006)

Amerikaner entdeckten "Omega minus"
por: Wolf, C
Publicado: (1964)

Assembly of minus endcap finished
por: Dick Loveless, et al.
Publicado: (2001)

Papillary Cyst of the Labium Minus
por: MacGregor, Jessie
Publicado: (1903)

Minus-Strand RNA Viruses
por: STRAUSS, JAMES H., et al.
Publicado: (2008)

Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer
por: Arcaroli, John, et al.
Publicado: (2012)

The effects of Src tyrosine kinase inhibitor, saracatinib, on the markers of epileptogenesis in a mixed-sex cohort of adult rats in the kainic acid model of epilepsy
por: Rao, Nikhil S., et al.
Publicado: (2023)

The momentum distribution of K+$\pi$$\minus$ and $\pi$+K$\minus$ pairs (Coulomb and nonCoulomb)
por: Gortchakov, O
Publicado: (2010)

Phenomenology of W plus or minus H plus or minus production at the CERN Large Handron Collider
por: Moretti, S, et al.
Publicado: (1998)

Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data
por: James, Gareth D., et al.
Publicado: (2016)

Novel Topology for (plus minus 600 A,plus minus 12 V) four-Quadrant Converter
por: Bordry, Frederick, et al.
Publicado: (1998)

Plus minus 2 x 7 Seiten für Ausarbeitungen, Nr. 14 /
por: Stockhausen, Karlheinz, 1928-
Publicado: (1978)

Omega-minus plus 25 years
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_lss86qmr1pan2ublrgm41cf8v7